Home MAPK Raf inhibitor PLX-4720 For research use only.

PLX-4720

PLX4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.

PLX-4720 Chemical Structure

PLX-4720 Chemical Structure

CAS: 918505-84-7

Selleck's PLX-4720 has been cited by 185 publications

Purity & Quality Control

Batch: Purity: 99.98%
99.98

Products often used together with PLX-4720

Dactolisib (BEZ235)

PLX-4720 and Dactolisib treatment decreases both pERK and pAKT levels in Colo-205 xenografts.

Schulte ML, et al. Mol Imaging Biol. 2017 Jun;19(3):421-428.

Navitoclax (ABT-263)

PLX-4720 and Navitoclax can enhance the clinical efficacy of BRAF inhibitors.

Frederick DT, et al. Cancer Res (2013) 73 (8_Supplement): 1724.

Dabrafenib

PLX-4720 and Dabrafenib dramatically reduce BRAF‐mutant melanoma cell death in response to the presence of CSF.

Seifert H, et al. Pigment Cell Melanoma Res. 2016 Jan;29(1):92-100.

NMS-E973

PLX-4720 and NMS-E973 show a synergic antiproliferative activity in A375 melanoma cells.

Fogliatto G, et al. Clin Cancer Res. 2013 Jul 1;19(13):3520-32.

SB431542

PLX-4720 and SB431542 cotreatment abolish the increase in cell growth caused by low-dose PLX-4720 in Colo829 and A375(M2) cells.

Spender LC, et al. Oncotarget. 2016 Dec 13; 7(50): 81995–82012.

PLX-4720 Related Products

Signaling Pathway

Raf Signaling Pathways

Raf Signaling Pathway

Choose Selective Raf Inhibitors

Cell Data

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
DU-4475 Growth Inhibition Assay IC50=0.07457 μM SANGER
EoL-1-cell Growth Inhibition Assay IC50=0.14166 μM SANGER
C32 Growth Inhibition Assay IC50=0.15131 μM SANGER
M14 Growth Inhibition Assay IC50=0.21757 μM SANGER
CP50-MEL-B Growth Inhibition Assay IC50=0.29784 μM SANGER
A101D Growth Inhibition Assay IC50=0.32589 μM SANGER
G-361 Growth Inhibition Assay IC50=0.34637 μM SANGER
HT-144 Growth Inhibition Assay IC50=0.36329 μM SANGER
ACN Growth Inhibition Assay IC50=0.38477 μM SANGER
COLO-829 Growth Inhibition Assay IC50=0.38968 μM SANGER
MEL-HO Growth Inhibition Assay IC50=0.41179 μM SANGER
SH-4 Growth Inhibition Assay IC50=0.41422 μM SANGER
SK-MEL-3 Growth Inhibition Assay IC50=0.51568 μM SANGER
A375 Growth Inhibition Assay IC50=0.67359 μM SANGER
MMAC-SF Growth Inhibition Assay IC50=0.68614 μM SANGER
BHT-101 Growth Inhibition Assay IC50=0.70702 μM SANGER
K5 Growth Inhibition Assay IC50=0.76148 μM SANGER
BV-173 Growth Inhibition Assay IC50=0.79644 μM SANGER
RVH-421 Growth Inhibition Assay IC50=0.86796 μM SANGER
HCC2218 Growth Inhibition Assay IC50=0.87844 μM SANGER
WM-115 Growth Inhibition Assay IC50=0.88692 μM SANGER
SK-MEL-28 Growth Inhibition Assay IC50=1.04569 μM SANGER
COLO-679 Growth Inhibition Assay IC50=1.10464 μM SANGER
MZ7-mel Growth Inhibition Assay IC50=1.14963 μM SANGER
SK-MEL-30 Growth Inhibition Assay IC50=1.33386 μM SANGER
NCI-H209 Growth Inhibition Assay IC50=1.6086 μM SANGER
HTC-C3 Growth Inhibition Assay IC50=1.66294 μM SANGER
KARPAS-45 Growth Inhibition Assay IC50=2.04978 μM SANGER
NCI-SNU-5 Growth Inhibition Assay IC50=2.11969 μM SANGER
KP-4 Growth Inhibition Assay IC50=2.30787 μM SANGER
PA-1 Growth Inhibition Assay IC50=2.72673 μM SANGER
HuO-3N1 Growth Inhibition Assay IC50=2.87946 μM SANGER
NCI-H358 Growth Inhibition Assay IC50=2.92232 μM SANGER
CTB-1 Growth Inhibition Assay IC50=3.40176 μM SANGER
697 Growth Inhibition Assay IC50=3.55266 μM SANGER
CP66-MEL Growth Inhibition Assay IC50=4.15927 μM SANGER
NB13 Growth Inhibition Assay IC50=4.49179 μM SANGER
DBTRG-05MG Growth Inhibition Assay IC50=4.53325 μM SANGER
A2058 Growth Inhibition Assay IC50=4.72164 μM SANGER
KG-1 Growth Inhibition Assay IC50=4.73908 μM SANGER
8305C Growth Inhibition Assay IC50=5.1873 μM SANGER
RPMI-7951 Growth Inhibition Assay IC50=5.80283 μM SANGER
CHL-1 Growth Inhibition Assay IC50=5.97603 μM SANGER
TI-73 Growth Inhibition Assay IC50=6.00902 μM SANGER
HT-1080 Growth Inhibition Assay IC50=6.10946 μM SANGER
ES5 Growth Inhibition Assay IC50=6.14924 μM SANGER
8-MG-BA Growth Inhibition Assay IC50=6.18129 μM SANGER
NB7 Growth Inhibition Assay IC50=6.21373 μM SANGER
H4 Growth Inhibition Assay IC50=6.22493 μM SANGER
CAL-72 Growth Inhibition Assay IC50=6.45423 μM SANGER
HCC1806 Growth Inhibition Assay IC50=6.81931 μM SANGER
BCPAP Growth Inhibition Assay IC50=7.21764 μM SANGER
LB2241-RCC Growth Inhibition Assay IC50=7.36907 μM SANGER
COLO-741 Growth Inhibition Assay IC50=8.01679 μM SANGER
HSC-3 Growth Inhibition Assay IC50=8.07068 μM SANGER
SW982 Growth Inhibition Assay IC50=8.41516 μM SANGER
GCT Growth Inhibition Assay IC50=8.75314 μM SANGER
KY821 Growth Inhibition Assay IC50=9.05178 μM SANGER
JVM-3 Growth Inhibition Assay IC50=9.56999 μM SANGER
RS4-11 Growth Inhibition Assay IC50=9.6048 μM SANGER
VA-ES-BJ Growth Inhibition Assay IC50=10.0149 μM SANGER
A431 Growth Inhibition Assay IC50=10.4212 μM SANGER
LXF-289 Growth Inhibition Assay IC50=10.458 μM SANGER
SK-MEL-24 Growth Inhibition Assay IC50=10.8274 μM SANGER
NOS-1 Growth Inhibition Assay IC50=10.8472 μM SANGER
KNS-62 Growth Inhibition Assay IC50=11.2404 μM SANGER
SK-HEP-1 Growth Inhibition Assay IC50=11.3527 μM SANGER
A3-KAW Growth Inhibition Assay IC50=11.7178 μM SANGER
SK-LU-1 Growth Inhibition Assay IC50=12.2655 μM SANGER
TYK-nu Growth Inhibition Assay IC50=12.3932 μM SANGER
NMC-G1 Growth Inhibition Assay IC50=12.6062 μM SANGER
BB65-RCC Growth Inhibition Assay IC50=12.7169 μM SANGER
QIMR-WIL Growth Inhibition Assay IC50=12.8833 μM SANGER
D-566MG Growth Inhibition Assay IC50=13.9576 μM SANGER
KYSE-140 Growth Inhibition Assay IC50=14.0753 μM SANGER
SCC-4 Growth Inhibition Assay IC50=14.3359 μM SANGER
U251 Growth Inhibition Assay IC50=14.8492 μM SANGER
D-542MG Growth Inhibition Assay IC50=14.9222 μM SANGER
LAMA-84 Growth Inhibition Assay IC50=14.9932 μM SANGER
NCI-H720 Growth Inhibition Assay IC50=15.2684 μM SANGER
DEL Growth Inhibition Assay IC50=15.4293 μM SANGER
SBC-1 Growth Inhibition Assay IC50=15.4305 μM SANGER
ECC10 Growth Inhibition Assay IC50=15.4458 μM SANGER
Daoy Growth Inhibition Assay IC50=15.7616 μM SANGER
SCH Growth Inhibition Assay IC50=15.7835 μM SANGER
MZ2-MEL Growth Inhibition Assay IC50=16.0646 μM SANGER
CAL-12T Growth Inhibition Assay IC50=16.4862 μM SANGER
KE-37 Growth Inhibition Assay IC50=16.8107 μM SANGER
LS-411N Growth Inhibition Assay IC50=17.118 μM SANGER
NCI-H2228 Growth Inhibition Assay IC50=17.3071 μM SANGER
SK-MEL-2 Growth Inhibition Assay IC50=17.4965 μM SANGER
HN Growth Inhibition Assay IC50=17.7248 μM SANGER
NCI-H1648 Growth Inhibition Assay IC50=17.818 μM SANGER
IA-LM Growth Inhibition Assay IC50=18.3172 μM SANGER
EW-13 Growth Inhibition Assay IC50=18.5708 μM SANGER
YKG-1 Growth Inhibition Assay IC50=19.5711 μM SANGER
KNS-81-FD Growth Inhibition Assay IC50=19.5858 μM SANGER
23132-87 Growth Inhibition Assay IC50=19.7642 μM SANGER
NUGC-3 Growth Inhibition Assay IC50=19.9887 μM SANGER
5637 Growth Inhibition Assay IC50=20.0478 μM SANGER
NCI-H1755 Growth Inhibition Assay IC50=20.4764 μM SANGER
RH-18 Growth Inhibition Assay IC50=20.5748 μM SANGER
RXF393 Growth Inhibition Assay IC50=20.6756 μM SANGER
LU-134-A Growth Inhibition Assay IC50=20.7056 μM SANGER
TE-12 Growth Inhibition Assay IC50=20.7201 μM SANGER
MOLT-4 Growth Inhibition Assay IC50=21.1915 μM SANGER
IGR-1 Growth Inhibition Assay IC50=21.3796 μM SANGER
HOP-92 Growth Inhibition Assay IC50=21.4987 μM SANGER
SK-MES-1 Growth Inhibition Assay IC50=21.7381 μM SANGER
LU-65 Growth Inhibition Assay IC50=21.8624 μM SANGER
MS-1 Growth Inhibition Assay IC50=22.1203 μM SANGER
LoVo Growth Inhibition Assay IC50=22.244 μM SANGER
A704 Growth Inhibition Assay IC50=22.5155 μM SANGER
HT-1376 Growth Inhibition Assay IC50=22.6059 μM SANGER
IST-MEL1 Growth Inhibition Assay IC50=22.6751 μM SANGER
Ramos-2G6-4C10 Growth Inhibition Assay IC50=22.7366 μM SANGER
T47D Growth Inhibition Assay IC50=22.7979 μM SANGER
HT-1197 Growth Inhibition Assay IC50=23.0817 μM SANGER
LB2518-MEL Growth Inhibition Assay IC50=23.6412 μM SANGER
J-RT3-T3-5 Growth Inhibition Assay IC50=24.7595 μM SANGER
SK-NEP-1 Growth Inhibition Assay IC50=24.8744 μM SANGER
NCI-H526 Growth Inhibition Assay IC50=25.0023 μM SANGER
IST-SL1 Growth Inhibition Assay IC50=25.2751 μM SANGER
HH Growth Inhibition Assay IC50=25.3192 μM SANGER
NCI-H82 Growth Inhibition Assay IC50=25.938 μM SANGER
SNU-449 Growth Inhibition Assay IC50=27.2018 μM SANGER
COR-L23 Growth Inhibition Assay IC50=27.2813 μM SANGER
LOXIMVI Growth Inhibition Assay IC50=27.368 μM SANGER
GR-ST Growth Inhibition Assay IC50=27.6706 μM SANGER
NCI-SNU-1 Growth Inhibition Assay IC50=27.944 μM SANGER
ALL-PO Growth Inhibition Assay IC50=28.1604 μM SANGER
ML-2 Growth Inhibition Assay IC50=28.2814 μM SANGER
HOP-62 Growth Inhibition Assay IC50=28.713 μM SANGER
EGI-1 Growth Inhibition Assay IC50=28.8845 μM SANGER
TCCSUP Growth Inhibition Assay IC50=28.9272 μM SANGER
LB996-RCC Growth Inhibition Assay IC50=29.5682 μM SANGER
LCLC-97TM1 Growth Inhibition Assay IC50=32.1964 μM SANGER
NCI-H1304 Growth Inhibition Assay IC50=32.3301 μM SANGER
KP-N-YS Growth Inhibition Assay IC50=32.5973 μM SANGER
NCI-H1770 Growth Inhibition Assay IC50=33.1648 μM SANGER
EM-2 Growth Inhibition Assay IC50=33.6504 μM SANGER
ChaGo-K-1 Growth Inhibition Assay IC50=33.7236 μM SANGER
ACHN Growth Inhibition Assay IC50=33.8385 μM SANGER
MN-60 Growth Inhibition Assay IC50=33.8544 μM SANGER
EW-18 Growth Inhibition Assay IC50=33.8971 μM SANGER
KGN Growth Inhibition Assay IC50=35.7292 μM SANGER
U031 Growth Inhibition Assay IC50=35.8132 μM SANGER
HMV-II Growth Inhibition Assay IC50=36.0774 μM SANGER
L-363 Growth Inhibition Assay IC50=37.6455 μM SANGER
NCI-H1155 Growth Inhibition Assay IC50=38.0015 μM SANGER
NCI-H1793 Growth Inhibition Assay IC50=38.1026 μM SANGER
P30-OHK Growth Inhibition Assay IC50=38.1332 μM SANGER
AN3-CA Growth Inhibition Assay IC50=38.1615 μM SANGER
UACC-257 Growth Inhibition Assay IC50=38.79 μM SANGER
MCF7 Growth Inhibition Assay IC50=39.8629 μM SANGER
KP-N-YN Growth Inhibition Assay IC50=40.4285 μM SANGER
T98G Growth Inhibition Assay IC50=40.4957 μM SANGER
HGC-27 Growth Inhibition Assay IC50=43.274 μM SANGER
NCI-H1092 Growth Inhibition Assay IC50=43.2895 μM SANGER
KARPAS-299 Growth Inhibition Assay IC50=43.3071 μM SANGER
LB1047-RCC Growth Inhibition Assay IC50=44.9959 μM SANGER
786-0 Growth Inhibition Assay IC50=45.65 μM SANGER
HCC2157 Growth Inhibition Assay IC50=46.0359 μM SANGER
NY Growth Inhibition Assay IC50=46.1778 μM SANGER
EFM-19 Growth Inhibition Assay IC50=46.7533 μM SANGER
EW-16 Growth Inhibition Assay IC50=46.7806 μM SANGER
UM-UC-3 Growth Inhibition Assay IC50=46.8059 μM SANGER
HT-29 Growth Inhibition Assay IC50=47.8792 μM SANGER
LN-405 Growth Inhibition Assay IC50=48.0827 μM SANGER
NCI-H727 Growth Inhibition Assay IC50=48.7726 μM SANGER
D-502MG Growth Inhibition Assay IC50=48.9676 μM SANGER
GMS-10 Growth Inhibition Assay IC50=49.2974 μM SANGER
MEL-JUSO Growth Inhibition Assay IC50=49.347 μM SANGER
insect cells Function assay Inhibition of N-terminal His-tagged BRAF V600E mutant (unknown origin) expressed in baculovirus infected insect cells co-expressing CDC37 using biotinylated-MEK as substrate by AlphaScreen assay, IC50 = 0.013 μM. 29461827
A375 Function assay Inhibition of BRAF V600E mutant in human A375 cells assessed as reduction in ERK phosphorylation by AlphaScreen assay, IC50 = 0.044 μM. 29461827
A375 Function assay Inhibition of b-Raf in human A375 cells assessed phosphorylation of ERK, IC50 = 0.046 μM. 22808911
A375 Antiproliferative assay Antiproliferative activity against human A375 cells expressing B-Raf V600E mutant and wild type Ras, IC50 = 0.5 μM. 22808911
A375 Cytotoxicity assay 72 hrs Cytotoxicity against human A375 cells harboring BRAF V600E mutant after 72 hrs by CellTiter-Glo assay, IC50 = 0.5 μM. 29461827
HCT116 Antiproliferative assay Antiproliferative activity against human HCT116 cells expressing wild type b-Raf and KRAS mutant, IC50 = 27 μM. 22808911
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells 29435139
Saos-2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells 29435139
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells 29435139
NB1643 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 29435139
Click to View More Cell Line Experimental Data

Biological Activity

Description PLX4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.
Targets
C-Raf-1 (Y340D/Y341D) [1]
(Cell-free assay)		 B-Raf (V600E) [1]
(Cell-free assay)		 BRK [1]
(Cell-free assay)		 B-Raf [1]
(Cell-free assay)
6.7 nM 13 nM 130 nM 160 nM
In vitro
In vitro PLX-4720 displays >10 times selectivity against wild type B-Raf, and >100 times selectivity over other kinases such as Frk, Src, Fak, FGFR, and Aurora A with IC50 of 1.3-3.4 μM. PLX-4720 significantly inhibits the ERK phosphorylation in cell lines bearing B-RafV600E with IC50 of 14-46 nM, but not the cells with wild-type B-Raf. PLX-4720 significantly inhibits the growth of tumor cell lines bearing the B-RafV600E oncogene, such as COLO205, A375, WM2664, and COLO829 with GI50 of 0.31 μM, 0.50 μM, 1.5 μM, and 1.7 μM, respectively. In addition, PLX-4720 treatment at 1 μM induces cell cycle arrest and apoptosis exclusively in the B-RafV600E-positive 1205Lu cells, but not in the B-Raf wild-type C8161 cells. [1] PLX-4720 treatment (10 μM) significantly induces >14-fold expression of BIM in the PTEN+ cells, compared with the PTEN- cell lines (4-fold), giving an explanation of the resistance of PTEN- cells to PLX-4720-induced apoptosis. [2]
Kinase Assay In vitro Raf kinase activities
The in vitro kinase activities of wild type Raf and mutants are determined by measuring phosphorylation of biotinylated-MEK protein using Perkin-Elmer's AlphaScreen Technology. For each enzyme (0.1 ng), 20-μL reactions are carried out in 20 mM Hepes (pH 7.0), 10 mM MgCl2, 1 mM DTT, 0.01% Tween-20, 100 nM biotin-MEK protein, various ATP concentrations, and increasing concentrations of PLX-4720 at room temperature. Reactions are stopped at 2, 5, 8, 10, 20, and 30 minutes with 5 μL of a solution containing 20 mM Hepes (pH 7.0), 200 mM NaCl, 80 mM EDTA, and 0.3% BSA. The stop solution also includes phospho-MEK Antibody, Streptavidin-coated Donor beads and Protein A Acceptor beads from the AlphaScreen Protein A Detection Kit. The antibody and beads are preincubated in stop solution in the dark at room temperature for 30 minutes. The final dilution of antibody is 1/2,000, and the final concentration of each bead is 10 μg/mL. The assay plates are incubated at room temperature for one hour then are read on a PerkinElmer AlphaQuest reader.
Cell Research Cell lines COLO205, A375, WM2664, COLO829, HT716, SW620, H460, Calu-6, HCT116, SK-MEL2, SK-MEL3, Lovo, H1299, 1205Lu, and C8161 cells
Concentrations Dissolved in DMSO, final concentrations ~1 mM
Incubation Time 24, 48, and 72 hours
Method Cells are treated with various concentrations PLX-4720 for 24, 48, and 72 hours. Cell proliferation is measured by using the CellTiter-Glo Luminescent Cell Viability Assay or MTT assay. For cell cycle analysis, supernatant and cells are collected, pelleted, and fixed with 70% ethanol. Before staining with propidium iodide (10 μg/mL), cells are incubated for 1 hour at 37 °C in 0.5 mg/mL RNase I to rid samples of residual RNA contamination. Samples are then analyzed by using the EPICS XL apparatus. For the assessment of apoptosis, media and cells are harvested and pelleted before staining with annexin-FITC and propidium iodide. Samples are subsequently analyzed by using the EPICS XL apparatus.
Experimental Result Images Methods Biomarkers Images PMID
Western blot pAkt(Ser473) / pAkt(Thr308) p27 / Cyclin D1 / pRb p-EGFR 1173 / EGFR / p-Akt / Akt p-MEK / MEK / p-ERK / ERK / p-FAK(S910) 21828154
Immunofluorescence ZKSCAN3 / TFEB LAMP1 30979895
Growth inhibition assay Cell viability 27848137
ELISA mIFN-γ 23204132
In Vivo
In vivo Oral administration of PLX-4720 at 20 mg/kg/day induces significant tumor growth delays and regressions in B-RafV600E-dependent COLO205 tumor xenografts, without obvious adverse effects in mice even at dose of 1 g/kg. PLX-4720 at 100 mg/kg twice daily almost completely eliminates the 1205Lu xenografts bearing B-RafV600E, while has no activity against C8161 xenografts bearing wild-type B-Raf. The anti-tumor effects of PLX-4720 correlate with the blockade of MAPK pathway in those cells harboring the V600E mutation. [1] PLX-4720 treatment at 30 mg/kg/day significant inhibits the tumor growth of 8505c xenografts by >90%, and dramatically decreases distant lung metastases. [3]
Animal Research Animal Models Female athymic mice (NCr nu/nu) implanted s.c. with COLO205 cells, and SCID mice with 1205Lu or C8161 cells
Dosages 5, 20, or 100 mg/kg
Administration Oral gavage once or twice daily

Chemical Information & Solubility

Molecular Weight 413.83 Formula

C17H14ClF2N3O3S
CAS No. 918505-84-7 SDF Download PLX-4720 SDF
Smiles CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)Cl)F
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 83 mg/mL ( (200.56 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
What would you recommend to make working solution for intraperitoneal injection into mice?

Answer:
PLX4720 has very limited solubility in aqueous solution and for this reason, we recommend oral gavage to administer this compound as not fully dissolved suspension can be used in oral gavage feeding.

Tags: buy PLX-4720|PLX-4720 ic50|PLX-4720 price|PLX-4720 cost|PLX-4720 solubility dmso|PLX-4720 purchase|PLX-4720 manufacturer|PLX-4720 research buy|PLX-4720 order|PLX-4720 mouse|PLX-4720 chemical structure|PLX-4720 mw|PLX-4720 molecular weight|PLX-4720 datasheet|PLX-4720 supplier|PLX-4720 in vitro|PLX-4720 cell line|PLX-4720 concentration|PLX-4720 nmr|PLX-4720 in vivo|PLX-4720 clinical trial|PLX-4720 inhibitor|PLX-4720 MAPK inhibitor